$IPSC News
Last published 4w ago
- 4w agoIPSCCentury Therapeutics to Attend 2026 Jefferies Global Healthcare Conference in LondonGlobeNewswirePHILADELPHIA, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. ((‘Century’, NASDAQ:IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for type 1 diabetes
- 2mo agoIPSCLRMRCentury Therapeutics Appoints Joseph Truitt to Board of DirectorsGlobeNewswirePHILADELPHIA, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. ((‘Century’, NASDAQ:IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune
- 3mo agoIPSCCentury Therapeutics Reports Second Quarter 2026 Financial Results and Business UpdatesGlobeNewswireCompleted pre-IND meeting with the FDA for CNTY-813, an iPSC-derived islet replacement therapy with functional cure potential in type 1 diabetes (T1D); IND submission on track for 4Q 2026CNTY-813 preclinical data from
- 4mo agoIPSCCentury Therapeutics Selected for Oral Presentations of CNTY-813 Preclinical Data at EASD 2026 and Breakthrough T1D® Clinical & Research Congress 2026GlobeNewswirePHILADELPHIA, July 09, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. ((‘Century’, NASDAQ:IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune
- 5mo agoIPSCNew CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026GlobeNewswireAdvancing CNTY-813 as a potential functional cure in Type 1 DiabetesCNTY-813 iPSC-derived islet replacement therapy demonstrates durable in-vivo glucose control maintained for more than eight months in preclinical
- 5mo agoGTBPIPHAINKTIPSCA Third Cancer Drug Just Entered the Clinic at an Under-$20-Million CompanyPR NewswireMost clinical-stage cancer companies with three drugs dosing patients in human trials carry valuations in the hundreds of millions, or more. GT...
- 6mo agoCRBPIPSCCorbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of DirectorsGlobeNewswireNORWOOD, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a clinical-stage company focused on developing promising new therapies in oncology and obesity, today announced the
- 6mo agoIPSCCentury Therapeutics Reports First Quarter Financial Results and Business UpdatesGlobeNewswireCNTY-813, Century's type 1 diabetes iPSC-derived islet therapy with functional-cure potential, remains on track for IND in 4Q 2026; initial clinical data expected in 2H 2027Upcoming oral presentation at the American
- 6mo agoIPSCCentury Therapeutics Selected for Oral Presentation of CNTY‑813 Preclinical Data at the American Diabetes Association 86th Scientific SessionsGlobeNewswirePHILADELPHIA, April 30, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. ((‘Century', NASDAQ:IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune
- 8mo agoIPSCCentury Therapeutics Reports Full Year 2025 Financial Results and Business UpdatesGlobeNewswireCNTY-813, lead beta islet cell therapy program as a potential functional cure for type 1 diabetes, in Investigational New Drug (IND)-enabling studies; IND submission expected in 4Q 2026 to support anticipated initial
- 8mo agoIPSCCentury Therapeutics to Participate in Upcoming Investor Conferences in MarchGlobeNewswirePHILADELPHIA, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. ((‘Century', NASDAQ:IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune
- 8mo agoFATEIPSCTYO:4593IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsightGlobeNewswireNew York, USA, Feb. 16, 2026 (GLOBE NEWSWIRE) -- IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight The iPSC-derived NK cells
- 10mo agoIPSCCentury Therapeutics Secures Oversubscribed $135 Million Private Placement Financing to Support Lead Program, CNTY-813, a Potentially Curative Therapy for Type 1 DiabetesGlobeNewswirePHILADELPHIA, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. ((‘Century', NASDAQ:IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune
- 11mo agoIPSCCentury Therapeutics Appoints Accomplished Biotechnology Leaders Dr. Han Lee and Dr. Martin Murphy to Board of DirectorsGlobeNewswirePHILADELPHIA, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. ((‘Century', NASDAQ:IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune
- 11mo agoIPSCCentury Therapeutics to Participate in Piper Sandler 37th Annual Healthcare ConferenceGlobeNewswirePHILADELPHIA, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. ((‘Century', NASDAQ:IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune
- 12mo agoIPSCCentury Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswireAnnounced iPSC derived beta islet cell program for Type 1 diabetes (T1D); Investigational New Drug (IND)-enabling studies expected to initiate by year-end 2025; IND submission planned in 2026CNTY-308 advancing through
- 12mo agoIPSCCentury Therapeutics Announces New Beta Islet Program for Type 1 DiabetesGlobeNewswireAllo-Evasion™ 5.0-engineered iPSC beta islets are designed to overcome immune rejection and provide durable glucose control without chronic immunosuppressionCompelling preclinical data demonstrate rapid reversal
- 1y agoIPSCCentury Therapeutics to Present at Chardan's 9th Annual Genetic Medicines ConferenceGlobeNewswirePHILADELPHIA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. ((‘Century', NASDAQ:IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune
- 1y agoIPSCCentury Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment ConferenceGlobeNewswirePHILADELPHIA, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. ((‘Century', NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in
- 1y agoIPSCCentury Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswirePatient dosing ongoing in CALiPSO-1 trial; on track to report clinical data for CNTY-101 in patients with B-cell-mediated autoimmune diseases by year-end 2025CNTY-308, a CAR-iT cell therapy functionally comparable to
- 1y agoIPSCCentury Therapeutics Announces Two Upcoming Presentations at the EULAR 2025 CongressGlobeNewswirePHILADELPHIA, May 28, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. ((‘Century', NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in
- 1y agoIPSCCentury Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswirePatient dosing initiated in Phase 1 CALiPSO-1 trial evaluating CNTY-101 in autoimmune disease; expanding to additional U.S. and European sites following CTA authorizations in Germany, France, and Italy CNTY-308 expected
- 1y agoIPSCCentury Therapeutics Announces Two Upcoming Presentations at the ASGCT 28th Annual MeetingGlobeNewswirePHILADELPHIA, April 28, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. ((‘Century', NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in
- 1y agoIPSCCentury Therapeutics to Host Live Fireside Chat Focused on Newly Prioritized Preclinical Cell Therapy Programs for Autoimmune Diseases and Cancer on Tuesday, April 22, 2025GlobeNewswirePHILADELPHIA, April 15, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. ((‘Century', NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in
- 1y agoIPSCCentury Therapeutics Reports Full Year 2024 Financial Results and Provides Business UpdateGlobeNewswirePreclinical pipeline re-prioritization to focus on four potentially transformative programs to advance toward clinic, led by CNTY-308 in B-cell mediated autoimmune diseases and malignancies New concentrated clinical
- 1y agoIPSCCentury Therapeutics Announces Investigator-Initiated Phase 1/2 Trial of its iPSC-derived iNK Cell Therapy CNTY-101 in B-cell Mediated Autoimmune Diseases Sponsored by Internationally Renowned Key Opinion LeadersGlobeNewswire- Investigator-initiated trial (IIT) to be led by pioneers of cell therapy in B-cell mediated autoimmune disease, the Schett/Mackensen group at Friedrich-Alexander University Erlangen-Nürnberg - - Trial to evaluate and
- 1y agoCGEMCRGXDCTHELVN+8Clear Street Launches Healthcare & Biotechnology Equity ResearchBusiness WireComprehensive Biotechnology sector market analysis and investment insights complement recently launched Disruptive Technology and Energy Transition franchises Clear Street, ("Clear Street", "the Company") a
- 1y agoIPSCCentury Therapeutics to Present at the Piper Sandler 36th Annual Healthcare ConferenceGlobeNewswirePHILADELPHIA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and
- 2y agoIPSCCentury Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdatesGlobeNewswire– Expansion of Phase 1 CALiPSO-1 trial of CNTY-101 in autoimmune disease to include diffuse cutaneous systemic sclerosis and idiopathic inflammatory myopathy – – Overall response rate (ORR) of 83% observed at CNTY-101
- 2y agoIPSCCentury Therapeutics Announces Upcoming Poster Presentations at the 2024 American Society of Hematology (ASH) Annual MeetingGlobeNewswire– Company to share preclinical data across diverse pipeline of iNK, γδ iT, and αβ iT cell therapy programs for oncology and autoimmune disease (AID) – – Preclinical data on development of iPSC-derived CD4+ and CD8+ CAR
- 2y agoIPSCCentury Therapeutics to Present at Guggenheim's Inaugural Healthcare Innovation ConferenceGlobeNewswirePHILADELPHIA, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and
- 2y agoIPSCCentury Therapeutics Strengthens Leadership Team with Appointments of Chief Financial Officer and Chief Scientific OfficerGlobeNewswire- Morgan Conn, Ph.D., seasoned biotech executive with expertise in financing, business development, and corporate strategy, appointed as Chief Financial Officer - - Chad Cowan, Ph.D., cell therapy pioneer, founder, and
- 2y agoIPSCCentury Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdatesGlobeNewswire– Initiation of Phase 1 CALiPSO-1 Trial of CNTY-101 in Systemic Lupus Erythematosus, marking strategic expansion into autoimmune disease; protocol amended to include additional cohort of Lupus Nephritis patients – –
- 2y agoIPSCCentury Therapeutics Presents Interim Results from Phase 1 ELiPSE-1 Study at ASCO 2024 Annual MeetingGlobeNewswireIn ongoing dose escalation, CNTY-101 has demonstrated a manageable safety profile with no observed DLTs or GvHD and with majority of patients treated in outpatient setting Encouraging preliminary efficacy in heavily
- 2y agoIPSCCentury Therapeutics Presents Preclinical Data Highlighting Advances in iPSC Platform Technology and Programs at 2024 ASGCT Annual MeetingGlobeNewswireIn vitro data showcases CNTY-101's ability to induce CD19-specific cytolysis of B-cells and potential to treat B-cell driven autoimmune diseases including systemic lupus erythematosus (SLE)Preclinical data demonstrates
- 2y agoIPSCCentury Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdatesGlobeNewswire- Announced plans to pursue additional autoimmune disease regulatory filings for its iPSC derived NK cell therapy, CNTY-101, beyond systemic lupus erythematosus (SLE) - Closed $60 million private placement led by Bain
- 2y agoIPSCCentury Therapeutics to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing SummitGlobeNewswirePHILADELPHIA, April 23, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and
- 2y agoIPSCCentury Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade TherapeuticsGlobeNewswireCentury is pursuing additional autoimmune disease regulatory filings for its iPSC derived iNK cell therapy, CNTY-101, beyond CALiPSO-1 trial in SLE, based on the potential of its differentiated profile
- 2y agoIPSCCentury Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual MeetingGlobeNewswirePHILADELPHIA, April 08, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and
- 2y agoIPSCMIRMRPHMSGMTSagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of DirectorsGlobeNewswireSAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to
- 2y agoIPSCCentury Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual ConferenceGlobeNewswirePHILADELPHIA, March 19, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and
- 2y agoIPSCCentury Therapeutics Reports Full Year 2023 Financial Results and Provides Business UpdatesGlobeNewswire- Presented initial data from Phase 1 ELiPSE-1 Trial of CNTY-101 in relapsed/refractory B-cell lymphomas demonstrating a favorable tolerability profile, early clinical activity and indication that Allo-Evasion™
- 2y agoIPSCCentury Therapeutics to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceGlobeNewswirePHILADELPHIA, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and
- 2y agoIPSCCentury Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ EditsGlobeNewswire– Data presented at 65th ASH Annual Meeting show CNTY-101 was generally well tolerated at Dose Level 1 (100 million cells) in a high-risk, heavily pretreated R/R B-cell lymphoma patient – – Preliminary clinical data
- 2y agoIPSCCentury Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus ErythematosusGlobeNewswirePHILADELPHIA, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and
- 2y agoIPSCCentury Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus ErythematosusGlobeNewswire– Represents second IND clearance for CNTY-101, the Company's lead iPSC-derived CD19-targeted CAR NK cell product candidate, and first in an autoimmune and inflammatory disease indication – – Company plans to initiate
- 2y agoIPSCCentury Therapeutics to Present at the Piper Sandler 35th Annual Healthcare ConferenceGlobeNewswirePHILADELPHIA, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today
- 3y agoIPSCCentury Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdatesGlobeNewswire- Brent Pfeiffenberger, Pharm.D., MBA, appointed Chief Executive Officer of Century Therapeutics - - Initial data from the ongoing Phase 1 ELiPSE-1 trial evaluating CNTY-101 in relapsed or refractory CD19 positive
- 3y agoIPSCCentury Therapeutics and FUJIFILM Cellular Dynamics Announce Licenses for the Development and Commercialization of iPSC-Derived Cell Therapies in Autoimmune and Inflammatory DiseasesGlobeNewswirePHILADELPHIA and MADISON, Wis., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (NASDAQ:IPSC), an innovative clinical-stage biotechnology company developing induced pluripotent stem cell (iPSC)-derived
- 3y agoIPSCCentury Therapeutics Appoints Brent Pfeiffenberger, Pharm.D., MBA, as Chief Executive OfficerGlobeNewswire- Accomplished leader with over 20 years of broad-ranging experience across the healthcare industry - Brent Pfeiffenberger, Pharm.D., MBA PHILADELPHIA, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc.